Literature DB >> 23186401

Demand for male contraception.

Emily Dorman1, David Bishai.   

Abstract

The biological basis for male contraception was established decades ago, but despite promising breakthroughs and the financial burden men increasingly bear due to better enforcement of child support policies, no viable alternative to the condom has been brought to market. Men who wish to control their fertility must rely on female compliance with contraceptives, barrier methods, vasectomy or abstinence. Over the last 10 years, the pharmaceutical industry has abandoned most of its investment in the field, leaving only nonprofit organisations and public entities pursuing male contraception. Leading explanations are uncertain forecasts of market demand pitted against the need for critical investments to demonstrate the safety of existing candidate products. This paper explores the developments and challenges in male contraception research. We produce preliminary estimates of potential market size for a safe and effective male contraceptive based on available data to estimate the potential market for a novel male method.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23186401     DOI: 10.1586/erp.12.52

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  14 in total

Review 1.  Male Contraception: Research, New Methods, and Implications for Marginalized Populations.

Authors:  Olivia Plana
Journal:  Am J Mens Health       Date:  2015-07-23

Review 2.  Continuing the search for a hormonal male contraceptive.

Authors:  Fiona Yuen; Brian T Nguyen; Ronald S Swerdloff; Christina Wang
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-02-19       Impact factor: 5.237

Review 3.  Male hormonal contraception: looking back and moving forward.

Authors:  M Y Roth; S T Page; W J Bremner
Journal:  Andrology       Date:  2015-10-09       Impact factor: 3.842

4.  Prolonged Oral Administration of a Pan-Retinoic Acid Receptor Antagonist Inhibits Spermatogenesis in Mice With a Rapid Recovery and Changes in the Expression of Influx and Efflux Transporters.

Authors:  Sanny S W Chung; Xiangyuan Wang; Debra J Wolgemuth
Journal:  Endocrinology       Date:  2016-01-26       Impact factor: 4.736

5.  Role of testis‑specific serine kinase 1B in undiagnosed male infertility.

Authors:  Tanya Kadiyska; Ivan Tourtourikov; Kristiyan Dabchev; Dilyana Madzharova; Savina Tincheva; Demetrios A Spandidos; Vassilis Zoumpourlis
Journal:  Mol Med Rep       Date:  2022-04-29       Impact factor: 3.423

Review 6.  Are men well served by family planning programs?

Authors:  Karen Hardee; Melanie Croce-Galis; Jill Gay
Journal:  Reprod Health       Date:  2017-01-23       Impact factor: 3.223

7.  Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial.

Authors:  Brian T Nguyen; Fiona Yuen; Maritza Farrant; Arthi Thirumalai; Frances Fernando; John K Amory; Ronald S Swerdloff; Bradley D Anawalt; Diana L Blithe; Jill E Long; Peter Y Liu; Stephanie T Page; Christina Wang
Journal:  Contraception       Date:  2021-06-18       Impact factor: 3.051

Review 8.  Human spermatozoa: revelations on the road to conception.

Authors:  R John Aitken
Journal:  F1000Prime Rep       Date:  2013-10-01

9.  Azoospermia in rabbits following an intravas injection of Vasalgel ™.

Authors:  Donald Waller; David Bolick; Elaine Lissner; Christopher Premanandan; Gary Gamerman
Journal:  Basic Clin Androl       Date:  2016-03-30

Review 10.  Male Hormonal Contraception: Where Are We Now?

Authors:  Christina Wang; Mario P R Festin; Ronald S Swerdloff
Journal:  Curr Obstet Gynecol Rep       Date:  2016-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.